Karydas Daphne
Director at MLYS
- Sold, on record
- $926k
- Dollars the filings state
- Form 4 sales
- 4
- Latest Sep 15, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- MLYSMineralys Therapeutics, Inc.Director
Sales by reason
3
Routine
0
Plan not stated
0
No plan
0
Unusual
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale MLYSUnusualNov 13, 2025 2025
Sold 15,000 shares at $45.99 ($690k)
Karydas Daphne, Director
No 10b5-1 planSold 100% of holdings ($690k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale MLYSRoutineMar 31, 2026 +138 days
Sold 3,000 shares at $25.00 ($75k)
Karydas Daphne, Director
10b5-1 planSold 32.6% of holdings ($230k position)6,200 shares leftFiling
- 3 Form 4 sale MLYSRoutineJun 17, 2026 +78 days
Sold 3,000 shares at $25.00 ($75k)
Karydas Daphne, Director
10b5-1 planSold 32.6% of holdings ($230k position)6,200 shares leftFiling
- 4 Form 4 sale MLYSRoutineSep 15, 2026 +90 days
Sold 3,000 shares at $28.58 ($86k)
Karydas Daphne, Director
10b5-1 planSold 32.6% of holdings ($263k position)6,200 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (4)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Sep 17, 2026 | MLYS | Director | Form 4 sale | 3,000 | $86k | 32.6% | Routine | SEC |
| Jun 17, 2026 | Jun 17, 2026 | MLYS | Director | Form 4 sale | 3,000 | $75k | 32.6% | Routine | SEC |
| Mar 31, 2026 | Apr 2, 2026 | MLYS | Director | Form 4 sale | 3,000 | $75k | 32.6% | Routine | SEC |
| Nov 13, 2025 | Nov 13, 2025 | MLYS | Director | Form 4 sale | 15,000 | $690k | 100.0% | Unusual | SEC |